Tender offer
- Sector
- Healthcare
- Industry
- Biological Products, (No Diagnostic Substances)
- Exchange
- —
- State of incorporation
- DE
- Form
- SC TO-T/A
- Filed
- May 30, 2025
Deal approval & antitrust
merger-arb riskA change of control closes only once its regulators clear it. These agencies have jurisdiction given the company's sector — track each one's docket for this deal. We link the official source; we do not assert an outcome.
Filings & documents
Every entry traces to SEC EDGAR. The Information Statement is the primary source; the links below open the full filing and each company's complete filing history.
Source filing ↗SC TO-T/A · the filing we parseAll documents in this filing ↗accession 0001193125-25-131545bluebird bio, Inc. — all SEC filings ↗EDGAR company pageCarlyle Partners Growth, L.P. — 8-K announcements ↗where the spin-off was announcedCarlyle Partners Growth, L.P. — all SEC filings ↗parent EDGAR company page